Lilly welcomes NICE's Victoza green light
This article was originally published in Scrip
Executive Summary
Lilly, which together with Amylin markets the first-in-class GLP-1 agonist Byetta (exenatide), has welcomed the final draft recommendations from NICE, the HTA institute for England and Wales, published last week, recommending Novo Nordisk's Victoza (liraglutide, also a GLP-1 agonist). Richard Ascroft, Lilly's director of corporate affairs, told Scrip that they were a good endorsement of the GLP-1 mechanism of action.